Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-12-23 08:19 |
PHARMING ANNOUNCES €8.4 MILLION CONVERTIBLE BOND FINANCING
|
English | 43.5 KB | ||
| 2011-12-16 08:36 |
PHARMING ANNOUNCES AGREEMENT WITH RENOVA LIFE TARGETING FACTOR VIII FOR THE TRE…
|
English | 172.4 KB | ||
| 2011-12-16 08:36 |
PHARMING ANNOUNCES AGREEMENT WITH RENOVA LIFE TARGETING FACTOR VIII FOR THE TRE…
|
English | 29.0 KB | ||
| 2011-12-12 08:21 |
PHARMING GRANTED U.S. PATENT ON C1 INHIBITOR USE IN ISCHEMIA REPERFUSION INJURY…
|
English | 164.5 KB | ||
| 2011-12-12 08:21 |
PHARMING GRANTED U.S. PATENT ON C1 INHIBITOR USE IN ISCHEMIA REPERFUSION INJURY…
|
English | 27.7 KB | ||
| 2011-12-09 08:36 |
PHARMING REPORTS ON NEGATIVE EQUITY POSITION AS A RESULT OF COMPLIANCE WITH IFRS
|
English | 168.5 KB | ||
| 2011-12-09 08:36 |
PHARMING REPORTS ON NEGATIVE EQUITY POSITION AS A RESULT OF COMPLIANCE WITH IFRS
|
English | 32.2 KB | ||
| 2011-12-07 07:39 |
SANTARUS AND PHARMING ANNOUNCE ORAL PRESENTATIONS OF RETROSPECTIVE ANALYSES OF …
|
English | 165.5 KB | ||
| 2011-11-17 08:42 |
Pharming reports financial results third quarter 2011
|
English | 233.3 KB | ||
| 2011-11-17 07:12 | English | 233.3 KB | |||
| 2011-11-04 08:35 |
Pharming And Santarus Announce Presentation Of Retrospective Analysis Of Data F…
|
English | 186.2 KB | ||
| 2011-08-31 13:43 |
Ruconest® launched in the Netherlands
|
Dutch | 156.2 KB | ||
| 2011-08-29 07:34 |
Pharming grants SOBI additional territories for the commercialisation of Rucone…
|
English | 187.1 KB | ||
| 2011-08-15 08:20 |
Pharming announces extension of their license agreement for the commercialisati…
|
English | 69.9 KB | ||
| 2011-08-04 08:29 |
Pharming and Santarus announce Special Protocol Assessment (SPA) Agreement with…
|
English | 201.5 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
